Revolution Medicines Inc RVMD Stock Analysis
- Nasdaq
- Stock
- Market open · closes 4:00 PM ET
$185.31 up $7.66, 4.31% today
As of · Tiingo real-time · Previous close $177.65
- Market cap
- $39.40BAt today’s price
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$8.85Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$185.31up $7.66, 4.31%Today
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Open$185.64Today
- Previous close$177.65Nov 5
- Volume7.81MNov 5 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume2.28MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- Today’s range: $181.45 to $189.77; now $185.31
The lowest and highest trades so far today. The marker shows the latest price.
- 52-week range: $58.91 to $224.31; now $185.31
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to today’s price. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
RVMD beat the S&P 500 in 4 of 6 periods.
| Period | RVMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RVMD: down 7.3% S&P 500: down 5.6% | RVMD trailed the S&P 500 by 1.7 percentage points Trailed |
| 3M | RVMD: down 6.3% S&P 500: down 4.1% | RVMD trailed the S&P 500 by 2.2 percentage points Trailed |
| YTD | RVMD: up 132.7% S&P 500: up 8.7% | RVMD beat the S&P 500 by 124.0 percentage points Beat |
| 1Y | RVMD: up 201.9% S&P 500: up 10.9% | RVMD beat the S&P 500 by 191.0 percentage points Beat |
| Long term | ||
| 3Y | RVMD: up 760.3% S&P 500: up 75.0% +104.9% vs +20.5% a year | RVMD beat the S&P 500 by 685.3 percentage points Beat |
| 5Y | RVMD: up 449.9% S&P 500: up 67.8% +40.6% vs +10.9% a year | RVMD beat the S&P 500 by 382.1 percentage points Beat |
$10,000 invested in RVMD 5 years ago (Nov 5, 2021) would be worth about $54,988 today, with dividends reinvested. The same amount in the S&P 500 would be worth about $16,784.
RVMD beat the S&P 500 in 4 of 6 periods.
| Period | RVMD and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | RVMD: down 7.3% S&P 500: down 5.6% | RVMD trailed the S&P 500 by 1.7 percentage points Trailed |
| 3M | RVMD: down 6.3% S&P 500: down 4.3% | RVMD trailed the S&P 500 by 2.0 percentage points Trailed |
| YTD | RVMD: up 132.7% S&P 500: up 7.8% | RVMD beat the S&P 500 by 124.9 percentage points Beat |
| 1Y | RVMD: up 201.9% S&P 500: up 9.7% | RVMD beat the S&P 500 by 192.2 percentage points Beat |
| Long term | ||
| 3Y | RVMD: up 760.3% S&P 500: up 68.8% +104.9% vs +19.1% a year | RVMD beat the S&P 500 by 691.5 percentage points Beat |
| 5Y | RVMD: up 449.9% S&P 500: up 57.0% +40.6% vs +9.4% a year | RVMD beat the S&P 500 by 392.9 percentage points Beat |
$10,000 invested in RVMD 5 years ago (Nov 5, 2021) would be worth about $54,988 today, not counting dividends. The same amount in the S&P 500 would be worth about $15,696.
All-time high
$221.15
Closing high on . Now 16.2% below that record.
Split-adjusted daily closes since Feb 13, 2020.
Stock splits
RVMD hasn’t split since its price history begins in 2020.
Valuation
Today’s price compared with the last 12 months of reported results (the four quarters to Jun 30, 2026). Tap a metric to see how it’s calculated.
Price-to-earnings (P/E)
n/mDiluted EPS of −$8.85 over the last 12 months
A P/E ratio isn’t meaningful while earnings over the last 12 months are negative. How to read P/E
Other valuation measures
- 15.1×Book value as of Jun 30, 2026
Price relative to accounting equity (book value) per share on the Jun 30, 2026 balance sheet. Asset-light companies often trade far above book value.
P/B = Price ÷ Book value per sharePrice-to-book ratio - −3.13%Last 12 months’ free cash flow
Free cash flow over the last 12 months as a share of the company’s market value: the cash the business generated for each dollar of stock.
FCF yield = Free cash flow (last 12 months) ÷ Market capFree cash flow - $36.64BAt today’s price
What it would cost to buy the whole business: the market cap at today’s price, plus debt, minus cash and short-term investments from the Jun 30, 2026 balance sheet.
EV = Market cap + Debt − Cash and short-term investmentsEV/EBITDA explained
Build your own RVMD DCF in Excel. Value Revolution Medicines with your own growth and margin assumptions.Browse DCF models Free DCF calculator
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $0.00
- Net income
- −$1.77B
- Diluted EPS
- −$8.85
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $0.00 | −$156.29M | −$0.94 |
| Q4 FY24 (Dec 31, 2024) | $0.00 | −$194.57M | −$1.13 |
| Q1 FY25 (Mar 31, 2025) | $0.00 | −$213.42M | −$1.13 |
| Q2 FY25 (Jun 30, 2025) | $0.00 | −$247.79M | −$1.31 |
| Q3 FY25 (Sep 30, 2025) | $0.00 | −$305.21M | −$1.61 |
| Q4 FY25 (Dec 31, 2025) | $0.00 | −$364.89M | −$1.89 |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$453.82M | −$2.29 |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$644.37M | −$3.06 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $29.39M | −$187.09M | −$2.57 |
| FY22 (Dec 31, 2022) | $35.38M | −$248.71M | −$3.08 |
| FY23 (Dec 31, 2023) | $11.58M | −$436.37M | −$3.86 |
| FY24 (Dec 31, 2024) | $0.00 | −$600.09M | −$3.58 |
| FY25 (Dec 31, 2025) | $0.00 | −$1.13B | −$5.95 |
Margins
- Gross —
- Operating —
- Net —
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$1.23BLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$1.22BLast 12 months
- Capital spending$9.10MLast 12 months
Shareholder returns
- $2.30BLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $3.99BAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$1.19BAs of Jun 30, 2026
- Net cash$2.79BAs of Jun 30, 2026
- 11.38As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.46As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- −96.4%Last 12 months
Over the last 12 months, Revolution Medicines lost money: its net loss was 96.4% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −63.2%Last 12 months
Over the last 12 months, Revolution Medicines’s net loss was 63.2% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Revolution Medicines Inc
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors RMC-6236, a RAS(ON) multi-selective inhibitor, RMC-6291, a RAS(ON) G12C-selective inhibitor, and RMC-9805, a RAS(ON) G12D-selective inhibitor, are currently in clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-5127 (G12V), RMC-0708 (Q61H) and RMC-8839 (G13C), in addition to RAS companion inhibitors RMC-4630 and RMC-5552.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
RVMD news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
RVMD stock FAQ
What is RVMD stock’s price today?
Revolution Medicines (RVMD) traded at $185.31 as of , up $7.66 (4.31%) from the previous close of $177.65. Over the past 52 weeks it has traded between $58.91 and $224.31.
If you invested $1,000 in RVMD 5 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in RVMD on would be worth about $5,499 today, a total return of +449.9%. The same $1,000 would be worth $3,019 if invested one year ago. Past performance doesn’t predict future returns.
What is Revolution Medicines’s market cap?
Revolution Medicines’s market capitalization is about $39.4 billion. That’s Tiingo’s daily market cap for , scaled to today’s price of $185.31 (how market cap works). Revolution Medicines reported 212.60M shares outstanding at the end of its latest quarter ().
What is RVMD’s P/E ratio?
RVMD’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$8.85).
What are RVMD’s earnings per share?
RVMD’s diluted earnings per share were −$8.85 over the four quarters to , compared with −$4.51 in the twelve months before. The latest quarter (Q2 FY26) brought −$3.06 per share, against −$1.31 a year earlier (how EPS works).
Does RVMD pay a dividend?
Revolution Medicines hasn’t paid a dividend in the last twelve months.
What is RVMD’s 52-week high and low?
Over the past 52 weeks RVMD has traded as low as $58.91 and as high as $224.31. At $185.31 today, it is 17.4% below that high and 214.5% above the low.
What is RVMD’s all-time high?
RVMD’s highest closing price was $221.15 on , adjusted for stock splits. At $185.31 today, it is 16.2% below that record.
Has RVMD stock ever split?
No. RVMD hasn’t split since its price history begins in 2020.
How has RVMD stock performed?
Including dividends and measured to today’s price, RVMD has returned +132.7% so far this year and +201.9% over the past year, and +449.9% over five years (+40.6% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Revolution Medicines in?
Revolution Medicines is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does RVMD trade on?
Revolution Medicines trades on the Nasdaq under the ticker symbol RVMD. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.